Welcome

發力腫瘤創新藥,KH815雙載荷設計有望提升分子療效注射用KH815是一種具有抗耐藥潛力的靶向滋養層細胞表

記者深入凱爾達了解到,五年來,該公司成功完成科創板上市,踏上資本市場新征程。華旺科技

Read More

Experience

【增減持】宏華數科:股東新湖智腦擬減持不超2.5%公司股份宏華數科公告,持股8.75%的浙江新湖智腦投資管理合夥企業(有限合夥)(

Read More

Resources

預計2025-2027年公司歸母淨利潤分別為61.49、66.48、73.37億元(前值分別為56.87、61.80、67.94億

Read More

Cases

 根據中康開思數據,僅從單一渠道看,康柏西普眼用注射液在2023年等級醫院銷售額同比增長35.1%,達18.15億元。長江通信:股

Read More

News & Events

[10-08-2015]

There are many variations of passages of Lorem Ipsum available, but the majority have suffered alteration in some form, by injected humour.

[10-08-2015]

There are many variations of passages of Lorem Ipsum available, but the majority have suffered alteration in some form, by injected humour.